Epidermolysis bullosa acquisita (EBA) is an acquired blistering skin disease characterized by the presence of IgG autoantibodies that recognize type VII (anchoring fibril) collagen. In this study, we have mapped the antigenic epitopes within the type VII collagen a chain by Western immunoblotting analysis with sera from 19 patients with EBA, using bacterial collagenase-or pepsin-resistant portions of type VII collagen and a panel of 12 recombinant fusion proteins corresponding to -80% of the primary sequence of the al (VII) collagen polypeptide. These studies identified four major immunodominant epitopes localized within the amino-terminal, noncollagenous (NC-1) domain. In addition to EBA, sera from three patients with bullous systemic lupus erythematosus (BSLE) were tested. The pattern of epitopes recognized by these sera were similar to those noted with EBA, suggesting that the same epitopes could serve as autoantigens in both blistering conditions. In contrast, sera from healthy controls or from patients with unrelated blistering skin diseases did not react with type VII collagen epitopes. Collectively, the results indicate that the immunodominant epitopes in EBA and BSLE lie within the noncollagenous regions oftype VII collagen. The precise role ofthe circulating autoantibodies in the pathogenesis of these blistering diseases remains to be elucidated. Conceivably, however, such antibodies could disrupt the assembly of type VII collagen into anchoring fibrils and/or interfere with their interactions with other extracellular matrix molecules within the cutaneous basement membrane zone. (J.
Introduction
Epidermolysis bullosa (EB)' is a group of both acquired and heritable disorders characterized by blistering of the skin and mucous membranes (1) (2) (3) . EB can be classified into three major categories on the basis of the level of tissue separation: (a) simplex, nonscarring forms; (b) junctional forms; and (c) dystrophic, scarring forms. Among the heritable forms ofEB, both autosomal dominant and autosomal recessive inheritance patterns can be recognized. In addition to inherited EB, an acquired autoimmune form of EB, known as EB acquisita (EBA), has been delineated (4, 5) . Patients with EBA have IgG autoantibodies which recognize type VII collagen (6) , the major component of anchoring fibrils located at the dermal-epidermal basement membrane zone (7, 8) . The clinical appearance of EBA patients and the histology of their cutaneous lesions are very reminiscent of hereditary dystrophic EB (6) . Furthermore, ultrastructural studies demonstrated a dramatic paucity of anchoring fibrils within the dermal-epidermal junction in both EBA and heritable forms of dystrophic EB (1-3, 9, 10) .
Type VII collagen is a homotrimer consisting ofthree identical subunit polypeptides, a 1 (VII) (8) . Recent cloning of human a 1 (VII) collagen complementary and genomic DNAs has allowed elucidation of the primary structure of type VII collagen (8, 11, 12) . The amino acid sequence information deduced from nucleotide sequences has predicted that type VII collagen consists of a -145 kD central collagenous domain characterized by a repeating Gly-X-Y amino acid sequence. However, the Gly-X-Y repeat sequence is interrupted by several imperfections, including a 39-amino acid noncollagenous segment (8) . The collagenous domain is flanked by a large, -145 kD noncollagenous domain, NC-1, and by a smaller, -20 kD noncollagenous domain, NC-2. Information from overlapping complementary and genomic DNA clones has unequivocally demonstrated that the NC-1 domain is the amino-terminal, while the NC-2 segment resides at the carboxy-terminal end of the molecule ( 12) . In the extracellular space, type VII collagen molecules form antiparallel dimers stabilized by disulfide bonding, and a portion of the NC-2 domain is proteolytically removed. Several of these antiparallel dimer molecules then laterally aggregate to form the anchoring fibrils. Thus, the tissue form of type VII collagen consists of a central collagenous domain, a large amino-terminal NC-1 domain, and a truncated carboxy-terminal NC-2 domain (8) .
Initial characterization of the autoantibodies in EBA suggested that they were directed against type VII collagen ( 13 
Methods
Patients' sera and antibodies. The sera used in these experiments were obtained from 19 patients with EBA. These patients all had an active, chronic, mechanobullous disorder with subepidermal blisters, as assessed by routine light microscopy of lesional skin. IgG deposits were detected within the sub-lamina densa region of the basement membrane zone below the epidermis oftheir skin using direct immunoelectron microscopy in all patients. Anti-type VII collagen antibodies circulating in their serum were identified by Western immunoblotting against type VII collagen extracted from human skin or purified from WISH cell-conditioned medium (6, 13, 14) . Because sera from patients with bullous systemic lupus erythematosus (BSLE) have been shown to have autoantibodies to type VII collagen (15) , three sera from patients with BSLE were tested. Controls included sera from healthy normal individuals of different ages (n = 5), patients with bullous pemphigoid (n = 3), pemphigus vulgaris (n = 2), pemphigus foliaceus (n = 2), and one patient with pemphigus paraneoplastica (16, 17) .
In addition to human sera, two mouse monoclonal antibodies, L3D and H3A ( 14, 18) ( 15) or biosynthetically derived from the conditioned medium of WISH cell cultures ( 14) , as well as pepsinized human type VII collagen ( 13) (Telios Pharmaceuticals, San Diego, CA), or bacterial collagenase-degraded type VII collagen were subjected to SDS-PAGE and Western immunoblotting as previously described (6, 19, 20) . All sera were tested at dilutions of 1:100 or greater. In various experiments, 10% polyacrylamide gels or 4-20% gradient polyacrylamide gels were used to examine a wide size range of potentially reactive proteins. In experiments with purified fusion proteins (see below), 3 ,g ofeach protein was electrophoresed and blotted. In some experiments with pepsinized type VII collagen, the gel lanes were overloaded with 10 ug of protein in order to insure that the amount ofprotein was sufficient to conclude definitively that the reaction with the sera was negative.
Epitope selection and immunoabsorption ofantibodies. To confirm the identity of each epitope and exclude a repeating motif within the fibronectin type III-like repeat ofthe NC-I domain ( Fig. 1) , immunoadsorption and epitopes selection were performed. Immunoreactive fusion proteins were blotted on nitrocellulose filters and incubated with EBA patients' serum diluted 1:100 (EBA 1 and EBA 7 of Fig. 3 and Table II ). EBA sera (containing unbound antibodies) were recouped and used for Western immunoblotting against the panel of fusion proteins. Antibodies bound to the fusion protein immobilized onto the nitrocellulose filters were eluted as described ( 11 ) The positions of the fusion proteins are indicated in Fig. 1 Immunofluorescence using epitope-selected antibodies on fusion protein was performed on normal human 1 M NaCi salt split skin in which dermis is separated from epidermis by fracture of the dermalepidermal junction as previously described (6) .
Constructsfor expression ofrecombinantfusion proteins. To generate fusion proteins corresponding to discrete segments within the a I(VII) collagen polypeptides, a series of constructs which express well-defined fusion proteins were developed (Fig. I A and Table I ). First, a construct containing an insert, FP4 corresponding to the a 1 (VII) collagen cDNA K-131 (11), was developed. For this purpose, the insert was isolated from the Bluescript plasmid by EcoRI restriction enzyme digestion. The insert was then subcloned into a pGEX vector (Pharmacia, Inc., Piscataway, NJ; modified by Dr. George Giudice, Medical College of Wisconsin) containing a Taq promoter and the glutathione-S-transferase (GST) gene, followed downstream by a thrombin cleavage site, a multiple cloning site for SmaI, BamHI, and EcoRI restriction enzymes, and a region with translation termination codons in all three reading frames (21) . This modified pGEX construct contained the EcoRI site in the correct reading frame to insure proper translation of the insert cDNA into protein.
Secondly, digestion of the cDNA FP4 with either NarI, Styl, or SmaI restriction endonuclease generated constructs FP5, FP6, or FP9, respectively. The digestion of FP4 with NarI was performed in the Bluescript vector, and with Styl in the modified pGEX vector. For digestion with SmaI, the cDNA FP4 was subcloned into the EcoRI site of the original pGEX-2T vector, followed by digestion with SmaI and religation.
Thirdly, a series ofdouble-stranded cDNAs corresponding to different regions ofthe alI (VII) collagen polypeptide was developed by PCR amplification of segments in the al (VII) collagen cDNAs (8, 11, 12) .
The upstream primers were synthesized to contain a BamHI site and the downstream primers contained an EcoRI site in their 5' ends, which allowed cloning ofthe cDNAs into the modified pGEX vector in correct orientation and reading frame, generating constructs FP 1, 3, 7, 8, 10, 11, and 12 (Table I) . In case the cDNA contained an internal BamHI site, both primers contained EcoRI sites in their 5' ends. One of the PCR-generated constructs, FP1, was digested with the PpuMI restriction enzyme to yield the construct FP2 (Fig. 1 A) . The correct orientation and reading frame of each insert cloned into the pGEX vector were determined by nucleotide sequencing of the cloning junctions (22) .
The constructs were transfected into Escherichia coli (DH5a) and grown to an OD of -0.5 at 600 nm in 1 liter ofLuria broth medium at 37°C. Subsequently, isopropyl f3-D-thiogalactopyranoside (in 0.5 mM final concentration) was added, and the incubations were continued for another 7 h. Bacteria were recovered by low-speed centrifugation and suspended in lysis buffer (150 mM NaCl, 16 mM NaH2HPO4, 4 mM Na2HPO4, 1 mM DTT, 1 mM EDTA, 1% Triton X100, 1% Tween 20, 1 mM PMSF, pH 7.2), followed by gentle sonication for 30 s on ice (21) . The sonicate was centrifuged at 10,000 g for 10 min, and the supernatant was collected. The pellet was reextracted using the same procedure, and the supernatants were combined.
To purify the fusion protein expressed in bacteria, the supernatants were applied to a column consisting ofagarose beads linked to glutathione in S-linkage (Sigma Chemical Co., St. Louis, MO). The bound proteins were eluted from the column by the addition of 5 (Table I) .
Results
Preparation of proteins for epitope mapping. All EBA sera tested in this study contained anti-basement membrane zone antibodies that (a) labeled the basement membrane zone between the epidermis and dermis by immunostaining, (b) exclusively labeled the dermal side ofsalt-split human skin substrate, and (c) reacted with the 290-300-kD al (VII) collagen chain by Western immunoblots of proteins extracted from human cutaneous basement membranes and proteins precipitated from conditioned medium of WISH cells (6, 13, 14) . As illustrated by Fig. 2 , the nonhelical, bacterial collagenase-resistant NC-I domain (Mr -145 kD) was readily recognized by all EBA sera tested (lane 2, panel A). In contrast, the type VII collagen a-chain devoid of the NC-I domain, (which was removed by pepsinization), was not recognized by any of the EBA sera (Fig. 2, lane 2, panel B) .
Using the pGEX expression vector annealed with the original a (VII) collagen cDNA FP4 ( 1 ), its truncated versions, or PCR products derived from segments of cloned type VII collagen cDNAs, we produced a series of fusion proteins encompassing 80% of the human type VII collagen molecule (Fig. 1 A) A. The symbols ++, +, and -indicate strongly positive, positive, and negative staining, respectively. The total number ofthe positive sera of the total three tested is indicated on the right.
FP1 OF SERUM #1
EBA sera tested reacted with one or more different epitopes within the NC-I domain (Table II and Fig. 1 B) . Within the NC-i domain, most of the fusion proteins recognized by the EBA autoantibodies corresponded to the fibronectin type IIIlike repeat region (8, 12) . Other subdomains outside of this area, but within the NC-I domain, such as the region with homology to the A domain ofvon Willebrand factor (vWF-A), were also recognized by several sera. Three distinct immunodominant epitopes within the fibronectin type III domain, as defined by fusion proteins FP 1, FP3, and the carboxyl-terminal half of FP7, were detected. These three epitopes were recognized by 18 out of 19 EBA sera tested (Table II) . The absence of cross reactivity among these three epitopes was demonstrated by immunoabsorption and immunofluorescence with affinity selected antibodies (Fig. 4) and also by the unique pattern of reactivity obtained with each individual serum. For example, serum 1 reacted only with FP1 whereas serum 2 reacted with FPl and FP3, and serum 14 reacted with FP7 (Table II) . Therefore, although these antigenic domains are confined within the fibronectin type III-like repeat region of the NC-1 domain, they are apparently distinct. Another immunodominant epitope was defined by reactivity with fusion proteins FP8 and FP4, but not with FP5 (Fig.  1) . 7 of 19 EBA sera, including serum 10, which did not react with other epitopes within the NC-I domain, showed strong labeling in this region (Table II) . This epitope corresponds to the carboxyl-terminal portion ofthe NC-domain with homology to the VWF-A sequence, and the cysteine-proline-rich region between the collagenous domain and the VWF-A region (Fig. 1) .
The antibodies were also tested for reactivity with three fusion proteins, FP9, FP0, and FP1 1, which correspond to the helical collagenous domain of the protein. No sera demonstrated reactivity with fusion proteins corresponding to the collagenous domain (Table II) . Furthermore, as indicated above, Western immunoblotting of the pepsin-resistant collagenous domain with 19 sera also yielded negative labeling (Fig. 2 B) . Thus, the triple-helical portion of type VII collagen does not contain major antigenic epitopes that can be recognized by EBA.
Taken together, these experiments make it clear that EBA autoantibodies are polyclonal and recognize multiple distinct epitopes across the span of the a 1 (VII) collagen chain, the major epitopes being within the noncollagenous NC-1 domain.
Western analyses with sera from patients with BSLE and other blistering skin diseases. Previous studies have shown that sera from patients with BSLE may contain autoantibodies to type VII collagen, while sera from SLE patients without blisters do not ( 15) . Three sera from patients with BSLE were examined in addition to the EBA sera. All three BSLE sera clearly recognized type VII collagen epitopes confined to NC-1 similar to that observed with the EBA sera (Table III, Figs. 1 and 3) . Thus, many of the same epitopes are recognized by BSLE and EBA autoantibodies.
In contrast to EBA and BSLE sera, the sera from normal subjects and patients with bullous pemphigoid or various forms of pemphigus (see Methods) did not react with any of the fusion proteins tested. The absence of reactivity of the fusion proteins with normal control sera or sera from patients with other bullous diseases attests to the specificity ofthe BSLE and EBA autoantibodies for type VII collagen. Epitope mapping oftwo monoclonal antibodies. In addition to the autoantibodies in the EBA sera, we examined two monoclonal anti-type VII collagen antibodies, H3A and L3D ( 15, 18) . By Western blot analysis, these two monoclonal antibodies reacted with the collagenase-resistant NC-1 domain and not with the collagenous portion ofthe molecule (data not shown). As expected with monoclonal antibodies, H3A and L3D demonstrated a more restricted epitope pattern within the type VII molecule than the EBA autoantibodies. Specifically, the L3D antibody did not recognize any fusion protein outside of FP4, and reacted with the fusion protein FP7, but not FP6 (Fig. 3) . These observations imply that the epitope for L3D must reside within the 75-amino acid region at the carboxyl end (3' region) of the peptide segment encoded by FP7. Furthermore, the monoclonal antibody H3A recognized only the fusion protein FP I (Fig. 3) . It is of interest that these two monoclonals react within the same regions on the type VII collagen molecule as the EBA sera, confirming the highly antigenic nature of these two regions (Fig. 1 B) . Fig. 3 for the complete reactivity against all the fusion proteins). Also, when the autoantibodies bound to the fusion protein are eluted and then used for indirect immunofluorescence on 1 M NaCl salt split skin, they label the dermal side of the dermal-epidermal junction (D) but not the epidermal side (E), identical to whole EBA sera.
Discussion
In this study, we examined discrete domains within the a 1 (VII) chain of type VII collagen for their ability to be recognized by the autoantibodies in the sera of patients with EBA and BSLE. All (Table II and Table  III) . Consequently, the bullous lesions in SLE, in many if not all cases, may be associated with a similar immunologic pathogenesis as noted in EBA blisters.
EBA is thought to be an autoimmune disease (4) . Although attempts to transfer passively the disease by injecting human antibodies into SCID mice with a human skin graft have been unsuccessful (24, 25) , it has been suggested that the autoantibodies play a role in the pathogenesis of the disease and that they are involved in mechanisms of epidermal-dermal disadherence in these patients (26, 27) . For example, type VII collagen has affinity for dermal fibronectin, a large noncollagenous glycoprotein. Thus, autoantibodies in EBA patients targeted against anchoring fibril collagen may interfere with the association between type VII collagen and fibronectin (27) . This may, in part, explain the mechanism of blister formation in EBA patients.
In the case of heritable forms of dystrophic EB, it is clear that genetic alterations which disturb the synthesis of type VII collagen or its assembly into functional anchoring fibrils, can explain the clinical phenotype (28, 29). In the case ofacquired EB, the basis for the development of autoantibodies is not clear, and there is no evidence for altered type VII collagen in EBA thus far. In this context, one hypothesis on the origin ofan autoimmune disease relates to "molecular mimicry" (30, 31 ) . In the case of EBA, the cross-reacting autoantibodies could prevent the assembly of type VII collagen into anchoring fibrils, interfere with the natural maintenance and turnover of anchoring fibrils, or interfere with the ability of the anchoring fibrils to stabilize the attachment of the basement membrane onto the underlying dermal connective tissues.
Our data argue against molecular mimicry as the basis of EBA, since we have identified EBA and BSLE autoantibodies that recognize multiple, apparently unrelated epitopes within the type VII collagen a-chain. It is possible, however, that the initial insult to the anchoring fibrils, mediated by an antibody recognizing a single epitope, could lead to exposure of additional epitopes and subsequent development of polyvalent antisera. Alternatively, the development of autoantibodies recognizing type VII collagen epitopes in patients with EBA may result from altered immunologic recognition of "self," in a manner similar to that seen in SLE and other autoimmune diseases (32, 33) . In this context, it is of interest that patients with BSLE, a subset of SLE who develop blisters in their skin, also develop autoantibodies recognizing type VII collagen epitopes ( 14) . As shown in this study, these patients' sera contain anti-type VII collagen antibodies that recognize similar epitopes as EBA antibodies, and these patients develop bullous lesions similar to those seen in EBA. These observations underscore the possibility that the circulating autoantibodies to type VII collagen are pathogenic in EBA.
